GlobeNewsWire
21 Jul 2026, 10:30 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Bluejay Diagnostics has completed patient enrollment for its pivotal SYMON-II clinical validation study ahead of schedule. — Completing a pivotal study's enrollment early reduces operational risk and accelerates the timeline toward potential regulatory submission.
+0.40The SYMON-II study will provide the primary clinical dataset used to support a 510(k) application to the FDA for the Symphony™ IL-6 platform. — This identifies the specific regulatory pathway (510(k)) and the critical nature of this study for the product's commercial viability.
+0.30Preliminary observations from the 750 enrolled patients show an approximately 17% 28-day mortality rate, which the company deems a robust dataset for prognostic evaluation. — A sufficient event rate (mortality) is necessary to prove the statistical significance of a prognostic test; this suggests the study is well-powered.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company successfully completed patient enrollment for a pivotal clinical study ahead of schedule, marking a key operational milestone toward regulatory submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
10h ago
